1 follower
Primmune Therapeutics is developing an orally administered TLR7 agonist to stimulate innate immunity in cancer immunotherapy. Their goal is to improve the response rate of patients to current and future immunotherapy medicines.
Industries
Headquarters
Stage
Employees
Links
Charles McDermott
View all
8 members
6 members
4 members
3 members
Twist Bioscience
6 followers
MindMed
4 followers
Adaptive Biotechnologies
10 followers
Agilent Technologies
60 followers
Regeneron
77 followers
Explore more companies